Tse 2372
2372.TTSE PRIME
Filed as I'rom Group Co., Ltd. (2022-06–2024-11)
Financials · Standalone
| Fiscal year ended | 2024-03 | 2023-03 | 2022-03 | 2021-03 | 2020-03 | 2019-03 |
|---|---|---|---|---|---|---|
| Revenue | ¥2.6bn | ¥3.4bn | ¥3.0bn | ¥2.0bn | ¥2.0bn | ¥1.8bn |
| Operating income | ¥301m | ¥1.8bn | ¥1.5bn | ¥526m | — | — |
| Ordinary income | ¥505m | ¥1.8bn | ¥1.6bn | ¥922m | ¥713m | ¥723m |
| Total assets | ¥20.6bn | ¥20.2bn | ¥15.5bn | ¥12.9bn | ¥10.6bn | ¥9.0bn |
| Net assets / equity | ¥8.7bn | ¥9.1bn | ¥8.2bn | ¥7.7bn | ¥6.9bn | ¥6.1bn |
| EPS (basic) | ¥31.21 | ¥117.34 | ¥92.69 | ¥72.55 | ¥65.45 | ¥59.54 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 2
| Period | Form | Figures |
|---|---|---|
| 2024-04-01 → 2024-09-30 | Half-year | 69 figures · EDINET |
| 2023-04-01 → 2024-03-31 | Annual | 207 figures · EDINET |
21 more reports are still being processed.
Segments · FY ended 2024-03
| Segment | External sales | Profit |
|---|---|---|
| Advanced Medical | ¥1.5bn | −¥133m |
| CRO | ¥6.4bn | ¥489m |
| Drug Discovery Business | — | −¥601m |
| Medical Support | ¥1.1bn | ¥66m |
| SMO | ¥8.7bn | ¥3.5bn |
| Other segments | ¥25m | −¥256m |
| Adjustments & eliminations | — | −¥1.9bn |
| Total | ¥17.7bn | ¥3.3bn |
| Total | ¥17.7bn | ¥3.1bn |
Segment names from EDINET member IDs; not mapped to a common taxonomy.